Biohaven’s verdiperstat gets fast-track designation

Biohaven’s myeloperoxidase inhibitor, verdiperstat, has received Fast Track designation from the FDA for the treatment of multiple system atrophy.

The FDA’s Fast Track designation provides for an expedited review of potential new drugs intended to treat serious conditions with high unmet need, allowing important new drugs to become available more quickly to patients suffering from serious conditions. more